Current Neuro-Oncology
Volume
13 Number 5
31 May 2011
Home > Publications > Current Neuro-Oncology > Volume 13, Year 2011 > Number 5, 31 May
*
Yordanova YN, Moritz-Gasser S,
Duffau H.
Awake
surgery for WHO Grade II gliomas within "noneloquent"
areas in the left dominant hemisphere: toward a "supratotal"
resection. Clinical article.
J
Neurosurg. 2011 May 6;115(2):232-9⍈.
doi: 10.3171/2011.3.JNS101333⍈.
PMID: 21548750⍈.
Retrospetive analysis. ⍈
Wefel
JS, Cloughesy T, Zazzali JL, Zheng M, Prados M, Wen PY, Mikkelsen
T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen
R, Vredenburgh J, Das A, Friedman HS.
Neurocognitive
function in patients with recurrent glioblastoma treated with
bevacizumab.
Neuro
Oncol. 2011 May 9. 2011;13(6):660-8. doi: 10.1093/neuonc/nor024⍈.
PMID: 21558074⍈.
Phase 2 trial. ⍈
Lassman
AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF,
Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG,
Roldán GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque
BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey
LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Panageas KS.
International
retrospective study of over 1000 adults with anaplastic
oligodendroglial tumors.
Neuro
Oncol. 2011 May 20. 2011;13(6):649-59. doi:
10.1093/neuonc/nor040⍈.
PMID: 21636710⍈.
Retrospective
analysis. ⍈
Weller
M.
Neurocognitive
function: an emerging surrogate endpoint for neuro-oncology
trials.
Neuro
Oncol. 2011 May 20. 2011;13(6):565. doi: 10.1093/neuonc/nor065⍈.
PMID: 21636704⍈.
Comment. ⍈
⤷Wefel
JS, et al. Neurocognitive function in patients with recurrent
glioblastoma treated with bevacizumab.
Neuro Oncol. 2011 May
9. 2011;13(6):660-8. doi: 10.1093/neuonc/nor024⍈.
PMID: 21558074⍈.
Phase 2 trial.
⍈